Dr. Foulkes joined Zymeworks in January 2024, bringing over 25 years of experience in the biotechnology, biopharma and medical device industries. Prior to joining Zymeworks, Dr. Foulkes was Chief Operating Officer of Arecor, a UK AIM-listed, clinical-stage biopharmaceutical company. Joining at the point of IPO, she implemented organizational and operational changes to position the company for future growth. Dr. Foulkes has held senior commercial roles covering corporate and business development, marketing and clinical portfolio management, with a therapeutic focus on immunology, inflammation, oncology and rare diseases. She has worked for organizations including Liminal Biosciences (previously known as Prometic Life Sciences), Acambis, and Cangene Corporation, and she was part of the start-up team for the medical device company, Nexan Ltd. Dr. Foulkes started her commercial career in management consultancy with McKinsey & Company and during her career she has also worked as a freelance consultant providing business development, strategy and market analysis support within the biotechnology industry, with a focus on oncology and immunology companies. Dr. Foulkes holds a PhD in Leukaemia Research and a BSc in Immunology, awarded by the University of Glasgow.